Sarcoglycanopathy
MONDO:0016140Deficiencies or mutations in the genes for the sarcoglycan complex subunits. A variety of phenotypes are associated with these mutations including a subgroup of autosomal recessive limb girdle muscular dystrophies, cardiomyopathies, and respiratory deficiency.
Also known as: qualitative or quantitative defects of sarcoglycan
10 clinical trials for this condition and its sub-types, 3 tagged with Sarcoglycanopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Sarcoglycanopathy
-
Qualitative or quantitative defects of beta-sarcoglycan 0 trials · 5 incl. sub-types
1 sub-type
-
Qualitative or quantitative defects of gamma-sarcoglycan 1 trial · 4 incl. sub-types
1 sub-type
-
Qualitative or quantitative defects of alpha-sarcoglycan 0 trials · 3 incl. sub-types
1 sub-type
-
Qualitative or quantitative defects of delta-sarcoglycan 0 trials · 2 incl. sub-types
2 sub-types
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC